CompaniesAntios Therapeutics

Antios Therapeutics

defunct
About

Defunct Company

Areas of Focus

Categories

Bankrupt, Merged, Sold, Renamed or Otherwise Defunct
Clinical Trials (6)
View all

Total Trials

6

As Lead Sponsor

6

As Collaborator

0

Total Enrollment

235

By Phase

PHASE2: 2PHASE1: 4

By Status

TERMINATED: 3COMPLETED: 3
Clinical Trials Pipeline6 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2019
2020
2021
2022
2023
Today
NCT04248426
NCT04847440
Hover over trial bars to see details

Recent Trials

NCT05238844Lead Sponsor
A Study of Safety and Efficacy of ATI-2173 and Vebicorvir in Combination With Tenofovir Disoproxil Fumarate in Subjects With Chronic Hepatitis B Virus Infection
PHASE2Terminated
2 participants
Started: Apr 11, 2022 · Completed: May 25, 2022
NCT05298332Lead Sponsor
Ethnobridging Study in Healthy Volunteers, Chinese and Japanese Subjects
PHASE1Terminated
37 participants
Started: Mar 29, 2022 · Completed: Aug 22, 2022
NCT05137600Lead Sponsor
A Drug-Drug Interaction Study Between ATI-2173 and Midazolam or Clarithromycin in Healthy Subjects
PHASE1Completed
36 participants
Started: Oct 28, 2021 · Completed: Jan 23, 2022
NCT05137548Lead Sponsor
A Drug-Drug Interaction Study Between ATI-2173 and Tenofovir Disoproxil Fumarate in Healthy Subjects
PHASE1Completed
32 participants
Started: Oct 27, 2021 · Completed: Dec 23, 2021
NCT04847440Lead Sponsor
A Study of Safety and Efficacy of ATI-2173 in Combination With Tenofovir Disoproxil Fumarate in Subjects With Chronic Hepatitis B Virus Infection and in Subjects With Hepatitis D Virus Coinfection
PHASE2Terminated
40 participants
Started: Mar 30, 2021 · Completed: Sep 1, 2022
View all 6 trials →
Funding History (4)
D
Nov 16, 2021
Filing
D
Apr 19, 2021
Filing
D
Aug 17, 2020
Filing
D
Dec 5, 2018
Filing